. (ALTH)
$1.84 0 (0.00%)
Market Cap: $0
As of 10/19/12 12:00 AM EDT. Market closed.
. (ALTH)
$1.84
0 (0.00%)
Market Cap: $0
As of 10/19/12 12:00 AM EDT. Market closed.
COMPANY PROFILE
Sector
Industry
URL
Address
.
Sector
Industry
URL
Address
.
PRICE CHART FOR
From:
To:
NEWS
KEY STATS
Open
$0
Previous Close
$1.84
Days Range
$0 - $0
52 week range
$0 - $0
Volume
0
Avg. Volume (30 days)
0
Market Cap
$0
Dividend Yield
0.00%
P/E
-
Shares Outstanding
0
Open
$0
Previous Close
$1.84
Days Range
$0 - $0
52 week range
$0 - $0
Volume
0
Avg. Volume (30 days)
0
Market Cap
$0
Dividend Yield
0.00%
P/E
-
Shares Outstanding
0
Open in: 
Open in:
INSIDER TRANSACTIONS FOR
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| SPECTRUM PHARMACEUTICALS INC | 10% Owner | Sep 05, 2012 | Buy | $1.82 | 130,854,840 | 238,155,816 | 1,000 | Sep 06, 2012, 05:15 PM |
| Warburg Pincus Private Equity VIII, L.P. | Director | Sep 05, 2012 | Option Exercise | $1.82 | 26,124,430 | 47,546,464 | 0 | Sep 06, 2012, 04:17 PM |
| TURNER JOSEPH L | Director | Sep 04, 2012 | Option Exercise | $1.82 | 55,000 | 100,100 | 0 | Sep 05, 2012, 04:55 PM |
| STOUT DAVID M | Director | Sep 04, 2012 | Option Exercise | $1.82 | 35,000 | 63,700 | 0 | Sep 05, 2012, 04:54 PM |
| LEFF JONATHAN S | Director | Sep 04, 2012 | Option Exercise | $1.82 | 55,000 | 100,100 | 0 | Sep 05, 2012, 04:53 PM |
| LATTS JEFFREY | Director | Sep 04, 2012 | Option Exercise | $1.82 | 55,000 | 100,100 | 0 | Sep 05, 2012, 04:52 PM |
| HOFFMAN STEPHEN J | Director | Sep 04, 2012 | Option Exercise | $1.82 | 200 | 364 | 0 | Sep 05, 2012, 04:50 PM |
| HOFFMAN STEPHEN J | Director | Sep 04, 2012 | Option Exercise | $1.82 | 472,871 | 860,625 | 0 | Sep 05, 2012, 04:50 PM |
| HOFFMAN STEPHEN J | Director | Sep 04, 2012 | Option Exercise | $1.82 | 92,000 | 167,440 | 0 | Sep 05, 2012, 04:50 PM |
| HOFFMAN STEPHEN J | Director | Sep 04, 2012 | Option Exercise | $1.82 | 200 | 364 | 0 | Sep 05, 2012, 04:50 PM |
| HOFFMAN STEPHEN J | Director | Sep 04, 2012 | Option Exercise | $1.82 | 200 | 364 | 0 | Sep 05, 2012, 04:50 PM |
| HOFFMAN STEPHEN J | Director | Sep 04, 2012 | Option Exercise | $1.82 | 200 | 364 | 0 | Sep 05, 2012, 04:50 PM |
| Schick Michael E | VP, Sales and Marketing | Sep 04, 2012 | Option Exercise | $1.82 | 285,113 | 518,906 | 0 | Sep 05, 2012, 04:48 PM |
| Morris Charles Q | Chief Medical Officer | Sep 04, 2012 | Option Exercise | $1.82 | 655,031 | 1,192,156 | 0 | Sep 05, 2012, 04:47 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Sep 04, 2012 | Option Exercise | $1.82 | 346,933 | 631,418 | 0 | Sep 05, 2012, 04:46 PM |
| Graboyes Marc H | SVP, General Counsel | Sep 04, 2012 | Option Exercise | $1.82 | 542,028 | 986,491 | 0 | Sep 05, 2012, 04:45 PM |
| Clark David C | VP, Finance | Sep 04, 2012 | Option Exercise | $1.82 | 207,114 | 376,947 | 0 | Sep 05, 2012, 04:44 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Sep 04, 2012 | Option Exercise | $1.82 | 148,482 | 270,237 | 0 | Sep 05, 2012, 04:43 PM |
| BERNS PAUL L | Chief Executive Officer | Sep 04, 2012 | Option Exercise | $1.82 | 1,233,323 | 2,244,648 | 0 | Sep 05, 2012, 04:41 PM |
| Schick Michael E | VP, Sales and Marketing | Jul 11, 2012 | Sale | $1.78 | 697 | 1,241 | 285,113 | Jul 13, 2012, 04:40 PM |
| Morris Charles Q | Chief Medical Officer | Apr 27, 2012 | Sale | $1.81 | 7,970 | 14,426 | 655,031 | May 22, 2012, 04:49 PM |
| Morris Charles Q | Chief Medical Officer | Feb 29, 2012 | Sale | $1.52 | 10,155 | 15,478 | 673,293 | May 22, 2012, 04:49 PM |
| Morris Charles Q | Chief Medical Officer | Mar 01, 2012 | Sale | $1.48 | 10,292 | 15,232 | 663,001 | May 22, 2012, 04:49 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Apr 27, 2012 | Buy | $1.22 | 1,104 | 1,342 | 148,482 | Apr 30, 2012, 04:59 PM |
| Morris Charles Q | Chief Medical Officer | Apr 27, 2012 | Sale | $1.81 | 7,970 | 14,426 | 665,323 | Apr 30, 2012, 04:58 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Mar 01, 2012 | Sale | $1.50 | 3,025 | 4,522 | 147,378 | Mar 01, 2012, 06:16 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Feb 29, 2012 | Sale | $1.53 | 3,031 | 4,623 | 150,403 | Mar 01, 2012, 06:16 PM |
| BERNS PAUL L | Chief Executive Officer | Feb 29, 2012 | Sale | $1.52 | 21,163 | 32,235 | 1,254,855 | Mar 01, 2012, 06:15 PM |
| BERNS PAUL L | Chief Executive Officer | Mar 01, 2012 | Sale | $1.48 | 21,532 | 31,816 | 1,233,323 | Mar 01, 2012, 06:15 PM |
| Clark David C | VP, Finance | Mar 01, 2012 | Sale | $1.50 | 3,385 | 5,073 | 207,114 | Mar 01, 2012, 06:15 PM |
| Clark David C | VP, Finance | Feb 29, 2012 | Sale | $1.52 | 3,388 | 5,165 | 210,499 | Mar 01, 2012, 06:15 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Mar 01, 2012 | Sale | $1.50 | 4,473 | 6,690 | 346,933 | Mar 01, 2012, 06:14 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Feb 29, 2012 | Sale | $1.52 | 4,505 | 6,869 | 351,406 | Mar 01, 2012, 06:14 PM |
| Graboyes Marc H | SVP, General Counsel | Feb 29, 2012 | Sale | $1.52 | 9,425 | 14,366 | 551,663 | Mar 01, 2012, 06:13 PM |
| Graboyes Marc H | SVP, General Counsel | Mar 01, 2012 | Sale | $1.48 | 9,635 | 14,260 | 542,028 | Mar 01, 2012, 06:13 PM |
| Morris Charles Q | Chief Medical Officer | Feb 29, 2012 | Sale | $1.52 | 10,155 | 15,478 | 673,293 | Mar 01, 2012, 06:13 PM |
| Schick Michael E | VP, Sales and Marketing | Mar 01, 2012 | Sale | $1.48 | 3,960 | 5,866 | 285,810 | Mar 01, 2012, 06:12 PM |
| Schick Michael E | VP, Sales and Marketing | Feb 29, 2012 | Sale | $1.52 | 3,894 | 5,935 | 289,770 | Mar 01, 2012, 06:12 PM |
| BERNS PAUL L | Chief Executive Officer | Feb 24, 2012 | Sale | $1.55 | 4,350 | 6,743 | 702,512 | Feb 27, 2012, 05:44 PM |
| BERNS PAUL L | Chief Executive Officer | Feb 23, 2012 | Sale | $1.56 | 9,100 | 14,196 | 706,862 | Feb 27, 2012, 05:44 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Feb 23, 2012 | Sale | $1.58 | 4,484 | 7,085 | 111,041 | Feb 27, 2012, 05:43 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Feb 24, 2012 | Sale | $1.55 | 1,469 | 2,277 | 109,572 | Feb 27, 2012, 05:43 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Feb 24, 2012 | Sale | $1.54 | 575 | 888 | 176,184 | Feb 27, 2012, 05:43 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Feb 23, 2012 | Sale | $1.58 | 2,500 | 3,958 | 176,759 | Feb 27, 2012, 05:43 PM |
| Clark David C | VP, Finance | Feb 24, 2012 | Sale | $1.55 | 595 | 922 | 114,108 | Feb 27, 2012, 05:42 PM |
| Clark David C | VP, Finance | Feb 23, 2012 | Sale | $1.57 | 1,460 | 2,291 | 114,703 | Feb 27, 2012, 05:42 PM |
| Schick Michael E | VP, Sales and Marketing | Feb 23, 2012 | Sale | $1.58 | 1,645 | 2,599 | 158,119 | Feb 27, 2012, 05:41 PM |
| Graboyes Marc H | SVP, General Counsel | Feb 24, 2012 | Sale | $1.54 | 1,380 | 2,125 | 338,822 | Feb 27, 2012, 05:40 PM |
| Graboyes Marc H | SVP, General Counsel | Feb 23, 2012 | Sale | $1.58 | 3,950 | 6,254 | 340,202 | Feb 27, 2012, 05:40 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Dec 30, 2011 | Buy | $1.21 | 1,173 | 1,416 | 115,525 | Jan 03, 2012, 04:42 PM |
| Clark David C | VP, Finance | Nov 16, 2011 | Sale | $1.43 | 125 | 179 | 116,163 | Nov 17, 2011, 05:08 PM |
| Clark David C | VP, Finance | Nov 15, 2011 | Sale | $1.45 | 5,438 | 7,861 | 116,288 | Nov 17, 2011, 05:08 PM |
| Graboyes Marc H | SVP, General Counsel | Nov 15, 2011 | Sale | $1.44 | 14,494 | 20,900 | 344,152 | Nov 17, 2011, 05:07 PM |
| Morris Charles Q | Chief Medical Officer | Nov 15, 2011 | Sale | $1.44 | 17,829 | 25,724 | 441,600 | Nov 17, 2011, 05:06 PM |
| Schick Michael E | VP, Sales and Marketing | Nov 16, 2011 | Sale | $1.43 | 140 | 201 | 159,764 | Nov 17, 2011, 05:05 PM |
| Schick Michael E | VP, Sales and Marketing | Nov 15, 2011 | Sale | $1.44 | 8,033 | 11,576 | 159,904 | Nov 17, 2011, 05:05 PM |
| BERNS PAUL L | Chief Executive Officer | Nov 16, 2011 | Sale | $1.43 | 450 | 643 | 715,962 | Nov 17, 2011, 05:04 PM |
| BERNS PAUL L | Chief Executive Officer | Nov 15, 2011 | Sale | $1.46 | 31,817 | 46,532 | 716,412 | Nov 17, 2011, 05:04 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Nov 16, 2011 | Sale | $1.43 | 300 | 430 | 179,259 | Nov 17, 2011, 05:03 PM |
| Goldsmith Bruce A | SVP, Corporate Development | Nov 15, 2011 | Sale | $1.44 | 12,465 | 18,008 | 179,559 | Nov 17, 2011, 05:03 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Nov 15, 2011 | Sale | $1.44 | 26,100 | 37,707 | 114,352 | Nov 17, 2011, 05:02 PM |
| Schick Michael E | VP, Sales and Marketing | Jul 11, 2011 | Sale | $2.06 | 730 | 1,505 | 167,937 | Jul 13, 2011, 04:21 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Jun 30, 2011 | Buy | $1.82 | 772 | 1,404 | 140,452 | Jul 01, 2011, 05:37 PM |
| Morris Charles Q | Chief Medical Officer | Apr 27, 2011 | Sale | $2.84 | 9,800 | 27,825 | 459,429 | Apr 29, 2011, 04:43 PM |
| BERNS PAUL L | Chief Executive Officer | Mar 17, 2011 | Option Exercise | $3.14 | 2,500 | 7,850 | 748,229 | Mar 18, 2011, 04:25 PM |
| Graboyes Marc H | SVP, General Counsel | Feb 24, 2011 | Sale | $3.13 | 1,410 | 4,406 | 187,843 | Feb 25, 2011, 05:29 PM |
| Graboyes Marc H | SVP, General Counsel | Feb 23, 2011 | Sale | $3.24 | 3,800 | 12,318 | 189,253 | Feb 25, 2011, 05:29 PM |
| Clark David C | VP, Finance | Feb 24, 2011 | Sale | $3.12 | 557 | 1,740 | 67,769 | Feb 25, 2011, 05:28 PM |
| Clark David C | VP, Finance | Feb 23, 2011 | Sale | $3.25 | 1,365 | 4,439 | 68,326 | Feb 25, 2011, 05:28 PM |
| BERNS PAUL L | Chief Executive Officer | Feb 24, 2011 | Sale | $3.12 | 4,255 | 13,293 | 399,787 | Feb 25, 2011, 05:28 PM |
| BERNS PAUL L | Chief Executive Officer | Feb 23, 2011 | Sale | $3.25 | 9,193 | 29,878 | 404,042 | Feb 25, 2011, 05:28 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Feb 24, 2011 | Sale | $3.20 | 1,469 | 4,701 | 95,915 | Feb 25, 2011, 05:27 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Feb 23, 2011 | Sale | $3.23 | 4,484 | 14,486 | 97,384 | Feb 25, 2011, 05:27 PM |
| Schick Michael E | VP, Sales and Marketing | Feb 23, 2011 | Sale | $3.25 | 1,570 | 5,105 | 103,667 | Feb 25, 2011, 05:26 PM |
| Goldsmith Bruce A | VP, Corporate Development | Feb 23, 2011 | Sale | $3.25 | 2,250 | 7,313 | 125,233 | Feb 25, 2011, 05:25 PM |
| Goldsmith Bruce A | VP, Corporate Development | Feb 24, 2011 | Sale | $3.12 | 507 | 1,583 | 124,726 | Feb 25, 2011, 05:25 PM |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | Dec 31, 2010 | Buy | $3.92 | 333 | 1,305 | 101,868 | Jan 04, 2011, 04:56 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| SPECTRUM PHARMACEUTICALS INC | 10% Owner | 09/05/2012 | 238,155,816 |
| Warburg Pincus Private Equity VIII, L.P. | Director | 09/05/2012 | 47,546,464 |
| TURNER JOSEPH L | Director | 09/04/2012 | 100,100 |
| STOUT DAVID M | Director | 09/04/2012 | 63,700 |
| LEFF JONATHAN S | Director | 09/04/2012 | 100,100 |
| LATTS JEFFREY | Director | 09/04/2012 | 100,100 |
| HOFFMAN STEPHEN J | Director | 09/04/2012 | 364 |
| HOFFMAN STEPHEN J | Director | 09/04/2012 | 860,625 |
| HOFFMAN STEPHEN J | Director | 09/04/2012 | 167,440 |
| HOFFMAN STEPHEN J | Director | 09/04/2012 | 364 |
| HOFFMAN STEPHEN J | Director | 09/04/2012 | 364 |
| HOFFMAN STEPHEN J | Director | 09/04/2012 | 364 |
| Schick Michael E | VP, Sales and Marketing | 09/04/2012 | 518,906 |
| Morris Charles Q | Chief Medical Officer | 09/04/2012 | 1,192,156 |
| Goldsmith Bruce A | SVP, Corporate Development | 09/04/2012 | 631,418 |
| Graboyes Marc H | SVP, General Counsel | 09/04/2012 | 986,491 |
| Clark David C | VP, Finance | 09/04/2012 | 376,947 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 09/04/2012 | 270,237 |
| BERNS PAUL L | Chief Executive Officer | 09/04/2012 | 2,244,648 |
| Schick Michael E | VP, Sales and Marketing | 07/11/2012 | 1,241 |
| Morris Charles Q | Chief Medical Officer | 04/27/2012 | 14,426 |
| Morris Charles Q | Chief Medical Officer | 02/29/2012 | 15,478 |
| Morris Charles Q | Chief Medical Officer | 03/01/2012 | 15,232 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 04/27/2012 | 1,342 |
| Morris Charles Q | Chief Medical Officer | 04/27/2012 | 14,426 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 03/01/2012 | 4,522 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 02/29/2012 | 4,623 |
| BERNS PAUL L | Chief Executive Officer | 02/29/2012 | 32,235 |
| BERNS PAUL L | Chief Executive Officer | 03/01/2012 | 31,816 |
| Clark David C | VP, Finance | 03/01/2012 | 5,073 |
| Clark David C | VP, Finance | 02/29/2012 | 5,165 |
| Goldsmith Bruce A | SVP, Corporate Development | 03/01/2012 | 6,690 |
| Goldsmith Bruce A | SVP, Corporate Development | 02/29/2012 | 6,869 |
| Graboyes Marc H | SVP, General Counsel | 02/29/2012 | 14,366 |
| Graboyes Marc H | SVP, General Counsel | 03/01/2012 | 14,260 |
| Morris Charles Q | Chief Medical Officer | 02/29/2012 | 15,478 |
| Schick Michael E | VP, Sales and Marketing | 03/01/2012 | 5,866 |
| Schick Michael E | VP, Sales and Marketing | 02/29/2012 | 5,935 |
| BERNS PAUL L | Chief Executive Officer | 02/24/2012 | 6,743 |
| BERNS PAUL L | Chief Executive Officer | 02/23/2012 | 14,196 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 02/23/2012 | 7,085 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 02/24/2012 | 2,277 |
| Goldsmith Bruce A | SVP, Corporate Development | 02/24/2012 | 888 |
| Goldsmith Bruce A | SVP, Corporate Development | 02/23/2012 | 3,958 |
| Clark David C | VP, Finance | 02/24/2012 | 922 |
| Clark David C | VP, Finance | 02/23/2012 | 2,291 |
| Schick Michael E | VP, Sales and Marketing | 02/23/2012 | 2,599 |
| Graboyes Marc H | SVP, General Counsel | 02/24/2012 | 2,125 |
| Graboyes Marc H | SVP, General Counsel | 02/23/2012 | 6,254 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 12/30/2011 | 1,416 |
| Clark David C | VP, Finance | 11/16/2011 | 179 |
| Clark David C | VP, Finance | 11/15/2011 | 7,861 |
| Graboyes Marc H | SVP, General Counsel | 11/15/2011 | 20,900 |
| Morris Charles Q | Chief Medical Officer | 11/15/2011 | 25,724 |
| Schick Michael E | VP, Sales and Marketing | 11/16/2011 | 201 |
| Schick Michael E | VP, Sales and Marketing | 11/15/2011 | 11,576 |
| BERNS PAUL L | Chief Executive Officer | 11/16/2011 | 643 |
| BERNS PAUL L | Chief Executive Officer | 11/15/2011 | 46,532 |
| Goldsmith Bruce A | SVP, Corporate Development | 11/16/2011 | 430 |
| Goldsmith Bruce A | SVP, Corporate Development | 11/15/2011 | 18,008 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 11/15/2011 | 37,707 |
| Schick Michael E | VP, Sales and Marketing | 07/11/2011 | 1,505 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 06/30/2011 | 1,404 |
| Morris Charles Q | Chief Medical Officer | 04/27/2011 | 27,825 |
| BERNS PAUL L | Chief Executive Officer | 03/17/2011 | 7,850 |
| Graboyes Marc H | SVP, General Counsel | 02/24/2011 | 4,406 |
| Graboyes Marc H | SVP, General Counsel | 02/23/2011 | 12,318 |
| Clark David C | VP, Finance | 02/24/2011 | 1,740 |
| Clark David C | VP, Finance | 02/23/2011 | 4,439 |
| BERNS PAUL L | Chief Executive Officer | 02/24/2011 | 13,293 |
| BERNS PAUL L | Chief Executive Officer | 02/23/2011 | 29,878 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 02/24/2011 | 4,701 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 02/23/2011 | 14,486 |
| Schick Michael E | VP, Sales and Marketing | 02/23/2011 | 5,105 |
| Goldsmith Bruce A | VP, Corporate Development | 02/23/2011 | 7,313 |
| Goldsmith Bruce A | VP, Corporate Development | 02/24/2011 | 1,583 |
| BENNETT BRUCE K JR | VP, Pharmaceutical Operations | 12/31/2010 | 1,305 |
Load More Insider Transactions